On October 5, 2023, Annette Matthies, Ph.D., Chief Business Officer of Elicio Therapeutics, Inc. (the ?Company?) was terminated without cause, effective as of the same date (the ?Separation Date?).
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
8.05 USD | -4.28% | -9.14% | -3.48% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.48% | 77.88M | |
+48.67% | 56.69B | |
-2.76% | 41B | |
+38.28% | 38.11B | |
-11.22% | 26.89B | |
+9.25% | 25.59B | |
-23.10% | 18.59B | |
+1.88% | 12.39B | |
+26.43% | 11.99B | |
+21.74% | 11.88B |
- Stock Market
- Equities
- ELTX Stock
- News Elicio Therapeutics, Inc.
- Elicio Therapeutics, Inc. Announces Resignation of Annette Matthies as Chief Business Officer